56 related articles for article (PubMed ID: 1569921)
1. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism.
Dayton JS; Turka LA; Thompson CB; Mitchell BS
Mol Pharmacol; 1992 Apr; 41(4):671-6. PubMed ID: 1569921
[TBL] [Abstract][Full Text] [Related]
2. Effects on in vivo and in vitro hepatocyte proliferation of methylprednisolone, azathioprine, mycophenolic acid, mizoribine, and prostaglandin E1.
Azzarone A; Francavilla A; Carrieri G; Gasbarrini A; Scotti-Foglieni C; Fagiuoli S; Cillo U; Zeng QH; Starzl TE
Transplant Proc; 1992 Dec; 24(6):2868-71. PubMed ID: 1465977
[No Abstract] [Full Text] [Related]
3. Hepatic growth effects of methylprednisolone, azathioprine, mycophenolic acid, and mizoribine.
Azzarone A; Francavilla A; Zeng QH; Starz TE
Transplantation; 1993 Jul; 56(1):219-21. PubMed ID: 8333047
[No Abstract] [Full Text] [Related]
4. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors.
Zeevi A; Yao GZ; Venkataramanan R; Duquesnoy RJ; Todo S; Fung JJ; Starzl TE
Transplant Proc; 1993 Feb; 25(1 Pt 1):781-3. PubMed ID: 7679843
[No Abstract] [Full Text] [Related]
5. Suppressive effects of Ganoderma lucidum on proliferation of peripheral blood mononuclear cells.
Kim RS; Kim HW; Kim BK
Mol Cells; 1997 Feb; 7(1):52-7. PubMed ID: 9085265
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of mizoribine prodrugs and their in vivo evaluation as immunosuppressive agents.
Gao LJ; Lin Y; De Jonghe S; Waer M; Herdewijn P
Bioorg Med Chem Lett; 2023 Oct; 95():129490. PubMed ID: 37770001
[TBL] [Abstract][Full Text] [Related]
7. Approaches Towards Better Immunosuppressive Agents.
Walczak J; Iwaszkiewicz-Grześ D; Cholewiński G
Curr Top Med Chem; 2024 Mar; ():. PubMed ID: 38561615
[TBL] [Abstract][Full Text] [Related]
8. Perforating dermatosis in a patient receiving azathioprine.
Grillo E; Vano-Galván S; Moreno C; Jaén P
Indian J Dermatol; 2013 Mar; 58(2):158. PubMed ID: 23716824
[TBL] [Abstract][Full Text] [Related]
9. Killing SCLC: insights into how to target a shapeshifting tumor.
Sutherland KD; Ireland AS; Oliver TG
Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Treatment Effect and Tolerance of the Topical Application of Mizoribine and Cyclosporine A in a Mouse Dry Eye Model.
Lin X; Wu Y; Tang L; Ouyang W; Yang Y; Liu Z; Wu J; Zheng X; Huang C; Zhou Y; Zhang X; Chen Y; Li W; Hu J; Liu Z
Transl Vis Sci Technol; 2020 Dec; 9(13):22. PubMed ID: 33364077
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression".
Roberts MB; Fishman JA
Clin Infect Dis; 2021 Oct; 73(7):e1302-e1317. PubMed ID: 32803228
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production.
von Borstel A; Abdulahad WH; Dekkema G; Rutgers A; Stegeman CA; Veldman J; Heeringa P; Sanders JS
PLoS One; 2020; 15(7):e0235743. PubMed ID: 32645052
[TBL] [Abstract][Full Text] [Related]
13. Regulation of ribosomal RNA synthesis in T cells: requirement for GTP and Ebp1.
Nguyen le XT; Lee Y; Urbani L; Utz PJ; Hamburger AW; Sunwoo JB; Mitchell BS
Blood; 2015 Apr; 125(16):2519-29. PubMed ID: 25691158
[TBL] [Abstract][Full Text] [Related]
14. [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
Schmidt S
Nervenarzt; 2010 Oct; 81(10):1231-41. PubMed ID: 20567960
[TBL] [Abstract][Full Text] [Related]
15. Mizoribine: a new approach in the treatment of renal disease.
Kawasaki Y
Clin Dev Immunol; 2009; 2009():681482. PubMed ID: 20052390
[TBL] [Abstract][Full Text] [Related]
16. De novo GMP synthesis is required for axon guidance in Drosophila.
Long H; Cameron S; Yu L; Rao Y
Genetics; 2006 Mar; 172(3):1633-42. PubMed ID: 16322525
[TBL] [Abstract][Full Text] [Related]
17. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity.
Ohtomo Y; Fujinaga S; Takada M; Murakami H; Akashi S; Shimizu T; Kaneko K; Yamashiro Y
Pediatr Nephrol; 2005 Dec; 20(12):1744-9. PubMed ID: 16133041
[TBL] [Abstract][Full Text] [Related]
18. Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.
Kamal MA; Jusko WJ
J Clin Pharmacol; 2004 Sep; 44(9):1034-45. PubMed ID: 15317831
[TBL] [Abstract][Full Text] [Related]
19. Targeted disruption of the inosine 5'-monophosphate dehydrogenase type I gene in mice.
Gu JJ; Tolin AK; Jain J; Huang H; Santiago L; Mitchell BS
Mol Cell Biol; 2003 Sep; 23(18):6702-12. PubMed ID: 12944494
[TBL] [Abstract][Full Text] [Related]
20. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine.
Bowen DG; Selby WS
Dig Dis Sci; 2000 Sep; 45(9):1810-3. PubMed ID: 11052324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
